Ankit Mahadevia, Director at Spero Therapeutics, Inc. (SPRO), sold 69,219 shares at $0.78 ($54K) on 2025-02-05, disclosed to the SEC on 2025-02-05.
Seasonal sale ($54k) by Director — this insider has traded SPRO in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.78 | 13,959 | $11K | 20.2% |
| 2 | $0.78 | 55,260 | $43K | 79.8% |
| Total | $0.78 avg | 69,219 | $54K | 100% |
| Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |
| SPRO | SELL | 2023-02-06 | $22K | — | Filing → |